Quick answer: Daraxonrasib (brand name Rasonque) is a once-daily pill that blocks RAS, the growth signal behind most pancreatic cancers. The FDA approved it on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma whose cancer got worse after at least one earlier treatment, or who can’t take combination chemotherapy. In the phase 3 RASolute 302 trial, people on daraxonrasib lived a median of 13.2 months, compared with 6.7 months on chemotherapy. It is not a cure, and it is not for everyone.
Top 3 Reasons Daraxonrasib Is Making Headlines
- Longer survival: Median overall survival nearly doubled compared with chemotherapy (13.2 vs. 6.7 months).
- A pill, not an infusion: You take 300 mg by mouth once a day.
- A different side-effect profile: Rash and mouth sores are common, but fewer people stopped treatment because of side effects than on chemotherapy.
Keep reading for eligibility details, a side-by-side chemo comparison, and what the approval means for patients in India.
What Is Daraxonrasib (Rasonque)?

Daraxonrasib (also called RMC-6236) is an oral targeted therapy made by Revolution Medicines. It is not chemotherapy. According to the U.S. Food and Drug Administration, the agency approved it as Rasonque on August 26, 2026, about 6.5 months ahead of its goal date. The drug had Breakthrough Therapy and Orphan Drug designations.
The American Association for Cancer Research (AACR) calls it the first RAS inhibitor approved for pancreatic cancer and the first pan-RAS inhibitor approved for any cancer type.
Daraxonrasib Quick Facts
| Generic name | Daraxonrasib (RMC-6236) |
|---|---|
| Brand name | Rasonque |
| Maker | Revolution Medicines, Inc. |
| Drug class | Oral RAS(ON) multi-selective inhibitor (targeted therapy) |
| FDA approval date | August 26, 2026 |
| Dose | 300 mg by mouth, once daily |
| Approved use | Metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or when multiagent therapy isn’t an option |
Why Pancreatic Cancer Needed a New Option
Doctors often find pancreatic cancer late. The five-year relative survival rate is just 13.7%, and the AACR notes that an estimated 67,530 Americans would be diagnosed and 52,740 would die from the disease in 2026, based on National Cancer Institute SEER data. Pancreatic adenocarcinoma is the most common type, according to Dana-Farber Cancer Institute.
How Does Daraxonrasib Work? The RAS Inhibitor Explained
Think of RAS proteins as on/off switches that tell cells when to grow. In most pancreatic cancers, a RAS gene (usually KRAS) has mutated, so the switch gets stuck in the “on” position. Cells keep dividing, and tumors grow and spread. RAS changes show up in about 9 out of 10 pancreatic cancers, according to Mass General Brigham.
A “Molecular Glue” That Targets Several RAS Types
Earlier RAS drugs target one specific mutation, KRAS G12C. That mutation appears in some lung and colorectal cancers, but it’s uncommon in pancreatic cancer. Daraxonrasib takes a broader approach. The AACR explains that it acts as a molecular glue: it bridges RAS with a helper protein called cyclophilin A, and that complex blocks RAS from passing growth signals to other proteins.
Because it isn’t tied to one mutation, daraxonrasib can act on several mutant and normal forms of RAS. Researchers also hope that makes it useful in other RAS-driven cancers.
“…could set the stage for a new era of pancreatic cancer treatment.”
Harsh Singh, MD, medical oncologist at Mass General Brigham Cancer Institute, on the FDA approval
Who Is Daraxonrasib For? Eligibility for Metastatic Pancreatic Cancer
The FDA approved daraxonrasib for adults who meet all of the following:
- Pancreatic adenocarcinoma, the most common type, which starts in the cells lining the pancreatic ducts.
- Metastatic (stage 4) disease, meaning the cancer has spread to places like the liver or lungs.
- Progression after at least one earlier systemic therapy, or an inability to take combination (multiagent) chemotherapy.
Who Daraxonrasib Is Not Approved For (Yet)
- Earlier-stage pancreatic cancer. The approval covers metastatic disease only.
- First-line treatment for most patients. A separate study is testing daraxonrasib, alone and with gemcitabine plus nab-paclitaxel, as a first treatment (NCT07491445).
- Other pancreatic tumor types. The approval covers adenocarcinoma only.
- People who are pregnant or planning a pregnancy. The FDA label includes an embryo-fetal toxicity warning. Ask your care team about birth control and breastfeeding before you start.
The FDA reports that the trial showed benefit both in people with a RAS G12 mutation and in the overall study population, and the approved use doesn’t name a specific RAS mutation. Still, ask your oncologist whether molecular testing belongs in your care plan.
RASolute 302 Results: Does Daraxonrasib Improve Survival?
The approval rests on RASolute 302, a randomized, open-label phase 3 trial. It enrolled 500 adults with metastatic pancreatic adenocarcinoma that progressed after one prior treatment. Researchers randomly assigned half to daraxonrasib and half to the physician’s choice of chemotherapy. After a median follow-up of 8.5 months (AACR), the FDA reports these results for the overall study population:
| Outcome | Daraxonrasib | Chemotherapy |
|---|---|---|
| Median overall survival | 13.2 months | 6.7 months |
| Median progression-free survival | 7.2 months | 3.6 months |
| Objective response rate (tumors shrank) | 30% | 11% |
| Risk of death (hazard ratio) | 0.40, or a 60% lower risk of death with daraxonrasib | |
Daraxonrasib vs. Chemotherapy in RASolute 302
Bars are scaled within each group. Source: FDA.
What “Median” Means for You
A median is the midpoint: half the people lived longer than 13.2 months, and half lived shorter. Some people did much better and some did worse, so these numbers can’t predict what will happen to any one person. Your oncologist can explain how they apply to your situation.
“…a landmark advance for patients with metastatic pancreatic cancer.”
Brian Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center at Dana-Farber and lead investigator of RASolute 302, in a Dana-Farber news release
Daraxonrasib Dosage: How to Take It
- The recommended dose is 300 mg by mouth once daily, continuing until the cancer progresses or side effects become unacceptable (FDA).
- Take it exactly as your oncologist and the prescribing information direct.
- Tell your care team about every prescription and over-the-counter medicine you take, because some drugs can change how Rasonque works or raise your risk of side effects.
Also Read: Pancreatic Cancer Vaccine: How It Works, Benefits, Side Effects
Daraxonrasib Side Effects: What to Expect
According to Dana-Farber Cancer Institute, the most common side effects in the trial were rash, mouth inflammation, nausea, and diarrhea. Mass General Brigham also lists vomiting. The FDA adds label warnings for several serious problems.
| Side effect or warning | What your care team may do |
|---|---|
| Rash and other skin problems | Skin creams, a preventive antibiotic, and help from a dermatologist |
| Mouth sores (stomatitis) | Ways to manage them if they develop |
| Diarrhea | Ways to manage it if it develops |
| Nausea and vomiting | Anti-nausea medicine prescribed with the drug |
| Serious label warnings: gastrointestinal perforation (a tear in the stomach or bowel wall) and interstitial lung disease or pneumonitis (lung inflammation) | Report a new cough, trouble breathing, or severe belly pain right away |
Mass General Brigham says the side effects are mostly manageable. In the study, more patients stopped chemotherapy because of side effects than stopped daraxonrasib, and its oncologist says patients often find the side effects easier to live with than chemo. Because the FDA label includes warnings for skin, mouth, and digestive problems, report symptoms early instead of waiting them out.
Call your care team promptly if you have: a spreading or painful rash, mouth sores that stop you from eating or drinking, diarrhea or vomiting that won’t stop, a new cough or trouble breathing, or severe belly pain.
Daraxonrasib vs. Chemotherapy: Side-by-Side Comparison
| Daraxonrasib (Rasonque) | Standard chemotherapy | |
|---|---|---|
| Type | Targeted therapy (RAS inhibitor) | Cytotoxic drugs that attack fast-dividing cells |
| How you take it | A daily pill at home | Usually scheduled treatments at a cancer center |
| Median overall survival (RASolute 302) | 13.2 months | 6.7 months |
| Median progression-free survival | 7.2 months | 3.6 months |
| Stopped treatment because of side effects | Fewer patients | More patients |
| Typical side effects | Rash, mouth sores, diarrhea, nausea | Low blood counts, fatigue, nerve damage (neuropathy) |
Survival figures come from the FDA. The treatment-stopping comparison comes from Mass General Brigham.
Is Daraxonrasib Available in India? Access and Cost
An FDA approval doesn’t automatically make a drug legal or available in India. India has its own drug regulator, the Central Drugs Standard Control Organization (CDSCO), and its own review process, so Rasonque would need Indian approval before routine marketing. The FDA notes that applications may still be under review at other regulatory agencies.
If you or a loved one lives in India, ask your oncologist about three things: whether a clinical trial fits, whether any legal access program exists, and what the expected cost and insurance coverage would be. Don’t buy this medicine from unverified online sellers.
What’s Next for RAS-Targeted Pancreatic Cancer Treatment
- Earlier-stage disease: Mass General Brigham says researchers plan to study daraxonrasib in cancer that hasn’t spread beyond the pancreas.
- First-line use: A new study is testing it as an initial treatment, with and without chemotherapy (NCT07491445).
- Other cancers: RAS changes also drive some lung and colorectal cancers, and Mass General Brigham’s oncologist expects this approach could help treat other RAS-linked cancers in the future.
Questions to Ask Your Oncologist About Daraxonrasib
- Does my cancer type and stage match the approved use?
- Should I have molecular testing first?
- How does daraxonrasib compare with my other options, including clinical trials?
- Which side effects should I watch for, and who do I call?
- Will it interact with my other medicines?
- What will it cost, and how do I get it?
Patient groups such as PanCAN and Let’s Win Pancreatic Cancer can also help you find trials and support.
Daraxonrasib FAQ
What is daraxonrasib used for?
Daraxonrasib (Rasonque) treats metastatic pancreatic adenocarcinoma in adults who have had at least one earlier systemic therapy or who can’t take combination chemotherapy.
Is daraxonrasib chemotherapy?
No. It is a targeted therapy that blocks RAS proteins instead of attacking all fast-dividing cells.
Does daraxonrasib cure pancreatic cancer?
No. In the trial, it extended survival and delayed cancer growth compared with chemotherapy, but the approval does not describe it as a cure.
What are the most common side effects?
Rash, mouth sores, diarrhea, nausea, and vomiting. The FDA label also warns about serious problems, including tears in the stomach or bowel wall and lung inflammation.
How much daraxonrasib do you take?
The recommended dose is 300 mg by mouth once daily, until the cancer progresses or side effects become unacceptable.
Daraxonrasib gives people with advanced pancreatic cancer a new, oral option that roughly doubled median survival compared with chemotherapy in a large phase 3 trial. It isn’t a cure, side effects like rash and mouth sores need active management, and access varies by country. If you’re considering it, talk with a cancer specialist who can match the evidence to your situation.
Last updated: November 21, 2026. Drug approvals, labels, and availability can change, so confirm current details with your care team and the FDA’s Drugs@FDA database.
Disclaimer: The information provided in this article is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician before starting any new health routine.






